Nonalcoholic steatohepatitis (NASH)
Do you have NASH?
Consider participating in the NN9500-4656 study evaluating three investigational drugs for their ability to treat Non-Alcoholic Steatohepatitis (NASH).
Join NN9500-4656 for up to 19 months of expert care where your health is in focus.
The NATiV3 Study is a clinical study evaluating an investigational drug as a potential treatment for people living with NASH. The investigational drug will potentially target 3 peroxisome proliferator-activated receptors which could lead to an increase in the ability of the body to regulate insulin, inflammation, and improve scarring of the liver caused by NASH.
GSK 218672 Glaxosmithkline Study
NASH is a condition affecting around 1 in 20 people or 5% of the world’s population. It occurs when fat that has built up in your liver causes damage and scarring of the liver. A study is being done to test if a potential new medicine can improve NASH.